# First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/first-line-erlotinib-versus-gemcitabine-cisplatin-in-patients-with-advanced-egfr/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Yi‐Long Wu,Caicun Zhou,Chong Kin Liam,Gang Wu,Xuan Liu,Zhaoyang Zhong,Shun Lü,Ying Cheng,Baohui Han,Lin Chen,Cheng Huang,Shanshan Qin,Yixiang Zhu,Hui Pan,Houjie Liang,Elizabeth Li,Guangliang Jiang,Soon Hin How,Mitchel Fernando,Y. Zhang,Fan Xia,Yanchen Zuo |
| Citations | 738 |
| DOI | 10.1093/annonc/mdv270 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2133149289 |
| PMID | 26105600 |
| Type | article |
| Year | 2015 |

## Paper authors

- [Yi‐Long Wu](https://scholariq.org/researchers/yi-long-wu/)
- [Ying Cheng](https://scholariq.org/researchers/ying-cheng/)
- [Gang Wu](https://scholariq.org/researchers/gang-wu/)
- [Chong Kin Liam](https://scholariq.org/researchers/chong-kin-liam/)

## Paper journal

- [Annals of Oncology](https://scholariq.org/journals/annals-of-oncology/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.